复星自研肺癌创新药上市申请获国家药监局受理

中金在线2025-03-11

近日，复星国际(00656.HK)旗下子公司复星医药宣布，其自主研发的1类新药丁二酸复瑞替尼胶囊的上市申请已获国家药品监督管理局受理。该新药主要用于治疗ALK阳性非小细胞肺癌、ROS1阳性非小细胞肺癌等，本次申报适应症为用于间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。复瑞替尼(Foritinib)是一种在研的高效、具有CNS高渗透性的ALK/ROS1抑制剂...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2518676495?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-11 14:47","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2518676495","market":"hk","top_or_hot":-1,"title":"复星自研肺癌创新药上市申请获国家药监局受理","media":"中金在线","content":"<div>\n<p>近日，复星国际(00656.HK)旗下子公司复星医药宣布，其自主研发的1类新药丁二酸复瑞替尼胶囊的上市申请已获国家药品监督管理局受理。该新药主要用于治疗ALK阳性非小细胞肺癌、ROS1阳性非小细胞肺癌等，本次申报适应症为用于间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。复瑞替尼(Foritinib)是一种在研的高效、具有CNS高渗透性的ALK/ROS1抑制剂...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031114505896410ad2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星自研肺癌创新药上市申请获国家药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星自研肺癌创新药上市申请获国家药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-11 14:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031114505896410ad2&s=b><strong>中金在线</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，复星国际(00656.HK)旗下子公司复星医药宣布，其自主研发的1类新药丁二酸复瑞替尼胶囊的上市申请已获国家药品监督管理局受理。该新药主要用于治疗ALK阳性非小细胞肺癌、ROS1阳性非小细胞肺癌等，本次申报适应症为用于间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。复瑞替尼(Foritinib)是一种在研的高效、具有CNS高渗透性的ALK/ROS1抑制剂...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031114505896410ad2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031114505896410ad2&s=b","article_id":"2518676495","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031114505896410ad2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2518676495","pubTimestamp":1741675630,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，复星国际旗下子公司复星医药宣布，其自主研发的1类新药丁二酸复瑞替尼胶囊的上市申请已获国家药品监督管理局受理。该新药主要用于治疗ALK阳性非小细胞肺癌、ROS1阳性非小细胞肺癌等，本次申报适应症为用于间变性淋巴瘤激酶阳性的局部晚期或转移性非小细胞肺癌患者的治疗。在2024年世界肺癌大会期间，复瑞替尼治疗ALK阳性非小细胞肺癌的III期REMARK研究的期中分析结果以最新突破性摘要形式公布。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK1515":"抗疫概念","02196":"复星医药","00656":"复星国际","BK1191":"制药","06978":"永泰生物-B","BK1574":"生物医药B类股","BK1161":"生物科技","BK1593":"医美概念股"},"translate_title":"Fosun's self-developed innovative lung cancer drug marketing application was accepted by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"06978":1,"02196":0.9,"00656":0.9},"content_text":"近日，复星国际(00656.HK)旗下子公司复星医药宣布，其自主研发的1类新药丁二酸复瑞替尼胶囊的上市申请已获国家药品监督管理局受理。该新药主要用于治疗ALK阳性非小细胞肺癌、ROS1阳性非小细胞肺癌等，本次申报适应症为用于间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。复瑞替尼(Foritinib)是一种在研的高效、具有CNS高渗透性的ALK/ROS1抑制剂，截至目前的临床研究显示，该新药在ALK阳性的非小细胞肺癌晚期患者中，展现出良好的临床疗效，对中枢神经系统转移灶疗效显著，且安全性良好。截至目前，该新药的另一适应症用于治疗非小细胞肺癌(ROS1+)于中国境内已完成II期临床研究。在2024年世界肺癌大会期间，复瑞替尼治疗ALK阳性非小细胞肺癌的III期REMARK研究的期中分析结果以最新突破性摘要(LBA)形式公布。在该研究中，复瑞替尼治疗组的PFS相较于克唑替尼减少了77%疾病进展或死亡的风险(PFS NR vs 13.93m，HR 0.23, 95% CI 0.14-0.38)，表明复瑞替尼是极具前景的用于治疗ALK阳性非小细胞肺癌的创新药物。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518676495","isCrawlerRequest":true}